Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387957 · ClinicalTrials.gov registry record · Phase 2
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
A Phase 2 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02387957: Clinical Trial Phase 2 study, sponsored by Ophthotech Corporation.
NCT02387957 is a Phase 2 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02387957, a Phase 2 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
Primary Outcome
Number of Patients with Systemic Adverse Events
Interventions
- DRUG bevacizumab
- DRUG ranibizumab
- DRUG aflibercept
- DRUG Fovista®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2016-04-26 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Why NCT02387957 stopped before completion
NCT02387957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 4 interventions - of which bevacizumab is the first listed.
NCT02387957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02387957 about?
NCT02387957 is a clinical study titled "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)". To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
What is the current status of trial NCT02387957?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2016-04-26. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02387957?
The interventions under investigation include: bevacizumab (DRUG), ranibizumab (DRUG), aflibercept (DRUG), Fovista® (DRUG).
Who is sponsoring clinical trial NCT02387957?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02387957's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI